Roche’s BTK inhibitor shines in multiple sclerosis trial
Roche has three ongoing Phase III trials of its BTK inhibitor fenebrutinib in patients with relapsing multiple sclerosis.
05 September 2024
05 September 2024
Roche has three ongoing Phase III trials of its BTK inhibitor fenebrutinib in patients with relapsing multiple sclerosis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.